Motley Fool Health-Care Analyst David Williamson discusses the earnings report and conference call released yesterday from Sarepta, and talks about why it may be the next biotech company to keep your eye on. Like any biotech company in the development stage, Sarepta didn't have a whole lot of earnings to report, but the conference call was full of great information. Williamson breaks down all the things he liked, and some of the things he didn't, from this exciting company's quarter.
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 10/17/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
- Arena Pharmaceuticals, inc (ARNA) Q2 2021 Earnings Call Transcript
- Arena Pharmaceuticals Inc (ARNA) Q1 2021 Earnings Call Transcript
- 3 Reasons to Avoid Arena Pharmaceuticals -- and 1 Reason to Buy
- Arena Pharmaceuticals Inc (ARNA) Q4 2020 Earnings Call Transcript
- Here's Why Arena Pharmaceuticals Stock Is Plummeting Today